Literature DB >> 14504630

Relation between the angiotensin-converting enzyme insertion/deletion polymorphism and blood pressure in Japanese male subjects.

M Todoroki1, J Minami, T Ishimitsu, M Ohrui, H Matsuoka.   

Abstract

Inconsistent results have been reported regarding the association of the angiotensin-converting enzyme (ACE) insertion/deletion (I/D) polymorphism and hypertension. Recent studies of population-based samples of three different areas in Japan presented conflicting results regarding this association. We, thus, investigated the relation between the ACE I/D polymorphism and blood pressure (BP), or the frequency of hypertension, respectively, in 706 Japanese male subjects who participated in the health check-up programme of our hospital. The ACE I/D polymorphism was determined by the polymerase chain reaction technique. Of 706 subjects, 203 were found to have hypertension and the other 503 were found to be normotensive. In all subjects, the frequencies of the DD, ID, and II genotypes were 0.123, 0.432, and 0.445, respectively, and the allelic frequency of the D allele was 0.339. In the younger subjects aged <50 years (n=264), neither systolic nor diastolic BP differed significantly among the genotypes. Conversely, in the older subjects aged > or =50 years (n=442), the systolic BP was significantly higher by 5.9 mmHg in the subjects with the ID genotype than those with the II genotype (P<0.01), and the diastolic BP was significantly higher in the subjects with the DD and ID genotypes by 5.1 and 3.3 mmHg, respectively than those with the II genotype (P<0.05 for each), although age, BMI, percentage of smoking habits, drinking habits, or the use of antihypertensive drugs did not differ significantly among the genotypes. In addition, in the older subjects, the hypertensive subjects showed significantly higher frequencies of the DD and ID genotypes and the D allele than the normotensive subjects. These results demonstrated that there was no significant association of the ACE I/D polymorphism with BP or a prevalence of hypertension in younger Japanese men aged <50 years but there was in older Japanese men aged > or =50 years.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14504630     DOI: 10.1038/sj.jhh.1001601

Source DB:  PubMed          Journal:  J Hum Hypertens        ISSN: 0950-9240            Impact factor:   3.012


  5 in total

1.  Insertion/deletion polymorphism of angiotensin converting enzyme gene in Korean hypertensive adolescents.

Authors:  Eun Young Park; Hye-Mi Ahn; Jung Ah Lee; Young Mi Hong
Journal:  Heart Vessels       Date:  2009-05-24       Impact factor: 2.037

2.  Five polymorphisms in gene candidates for cardiovascular disease in Afro-Brazilian individuals.

Authors:  Tatsuya Sakuma; Rosario D C Hirata; Mario H Hirata
Journal:  J Clin Lab Anal       Date:  2004       Impact factor: 2.352

3.  High Incidence of ACE/PAI-1 in Association to a Spectrum of Other Polymorphic Cardiovascular Genes Involving PBMCs Proinflammatory Cytokines in Hypertensive Hypercholesterolemic Patients: Reversibility with a Combination of ACE Inhibitor and Statin.

Authors:  Jeanne d'Arc AlBacha; Mira Khoury; Charbel Mouawad; Katia Haddad; Samar Hamoui; Albert Azar; Ziad Fajloun; Nehman Makdissy
Journal:  PLoS One       Date:  2015-05-14       Impact factor: 3.240

Review 4.  Genetic polymorphisms associated with reactive oxygen species and blood pressure regulation.

Authors:  Santiago Cuevas; Van Anthony M Villar; Pedro A Jose
Journal:  Pharmacogenomics J       Date:  2019-02-06       Impact factor: 3.550

5.  Angiotensin-converting enzyme insertion/deletion polymorphism, 24-h blood pressure profile and left ventricular hypertrophy in hypertensive individuals: a cross-sectional study.

Authors:  Luciana Neves Cosenso-Martin; Renan Oliveira Vaz-de-Melo; Luana Rocco Pereira; Cláudia Bernardi Cesarino; Juan Carlos Yugar-Toledo; José Paulo Cipullo; Marcela Augusta de Souza Pinhel; Dorotéia Rossi Silva Souza; José Fernando Vilela-Martin
Journal:  Eur J Med Res       Date:  2015-09-04       Impact factor: 2.175

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.